TIMP-1 Promotes Accumulation of Cancer Associated Fibroblasts and Cancer Progression

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Gong, Yixuan ^a   Scott, Evita ^a   Lu, Rong ^a   Xu, Yin ^a   Oh, William K ^a   Yu, Qin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER TISSUE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; STROMA; TUMOR MICROENVIRONMENT;

ANIMALS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; ENZYME ACTIVATION; FIBROBLASTS; HUMANS; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROSTATIC NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84885460617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077366     Document Type: Article

References (56)

1. Courtney KD, Taplin ME, (2012) The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. Curr Opin Oncol 24: 272-277. doi:10.1097/CCO.0b013e328351059d. PubMed: 22327837.
2. Tsao CK, Small AC, Galsky MD, Oh WK, (2012) Overcoming castration resistance in prostate cancer. Curr Opin Urol 22: 167-174. doi:10.1097/MOU.0b013e3283523b8b. PubMed: 22472508.
3. Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F, (2012) Novel strategies in the treatment of castration-resistant prostate cancer (Review). Int J Oncol 40: 1313-1320 PubMed: 22322981.
4. Osanto S, Van Poppel H, (2012) Emerging novel therapies for advanced prostate cancer. Ther Adv Urol 4: 3-12. doi:10.1177/1756287211432777. PubMed: 22295041.
5. Corcoran NM, Gleave ME, (2012) Targeted therapy in prostate cancer. Histopathology 60: 216-231. doi:10.1111/j.1365-2559.2011.04030.x. PubMed: 22212088.
6. Bourboulia D, Stetler-Stevenson WG, (2010) Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20: 161-168. doi:10.1016/j.semcancer.2010.05.002. PubMed: 20470890.
7. Stamenkovic I, (2000) Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10: 415-433. doi:10.1006/scbi.2000.0379. PubMed: 11170864.
8. Birkedal-Hansen H, Yamada S, Windsor J, Pollard AH, Lyons G, et al. (2008) Matrix metalloproteinases. Curr Protoc Cell Biol Chapter 10Unit 10 18.
9. Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, et al. (1995) Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer 63: 680-687. doi:10.1002/ijc.2910630513. PubMed: 7591285.
10. Chetty C, Lakka SS, Bhoopathi P, Kunigal S, Geiss R, et al. (2008) Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res 68: 4736-4745. doi:10.1158/0008-5472.CAN-07-6612. PubMed: 18559520.
11. Deng X, He G, Levine A, Cao Y, Mullins C, (2008) Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer. Int J Cancer 122: 209-218. doi:10.1002/ijc.23053. PubMed: 17847032.
12. Gu P, Xing X, Tänzer M, Röcken C, Weichert W, et al. (2008) Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia 10: 563-572. PubMed: 18516293.
13. Zhang H, Wang YS, Han G, Shi Y, (2007) TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. Hepatobiliary Pancreat Dis Int 6: 487-491. PubMed: 17897911.
14. Stetler-Stevenson WG, (2008) Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1re6-: re6 PubMed: 18612141.
15. Schelter F, Grandl M, Seubert B, Schaten S, Hauser S, et al. (2011) Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin Exp Metastasis, 28: 793-802. PubMed: 21789719.
16. Fu ZY, Lv JH, Ma CY, Yang DP, Wang T, (2011) Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-small ka, CyrillicB pathway. Biomed Pharmacother 65: 163-167. doi:10.1016/j.biopha.2011.02.004. PubMed: 21684102.
17. Stetler-Stevenson WG, (2008) The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev 27: 57-66. doi:10.1007/s10555-007-9105-8. PubMed: 18058195.
18. Hoegy SE, Oh HR, Corcoran ML, Stetler-Stevenson WG, (2001) Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem 276: 3203-3214. doi:10.1074/jbc.M008157200. PubMed: 11042184.
19. Clark IM, Swingler TE, Sampieri CL, Edwards DR, (2008) The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40: 1362-1378. doi:10.1016/j.biocel.2007.12.006. PubMed: 18258475.
20. Fisher JF, Mobashery S, (2010) Mechanism-based profiling of MMPs. Methods Mol Biol 622: 471-487. doi:10.1007/978-1-60327-299-5_27. PubMed: 20135299.
21. Fu X, Parks WC, Heinecke JW, (2008) Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol 19: 2-13. doi:10.1016/j.semcdb.2007.06.005. PubMed: 17689277.
22. Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, et al. (2011) Overexpression of Fn14 Promotes Androgen Independent Prostate Cancer Progression through MMP-9 and Correlates with Poor Treatment Outcome. Carcinogenesis.
23. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG, (1995) Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1: 899-906. PubMed: 9816060.
24. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, et al. (2002) Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 197: 307-313. doi:10.1002/path.1129. PubMed: 12115876.
25. Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, et al. (2011) Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. Cancer 117: 517-525. doi:10.1002/cncr.25394. PubMed: 20862742.
26. Aldulaymi B, Byström P, Berglund A, Christensen IJ, Brünner N, et al. (2010) High plasma TIMP-1 and serum CEA levels during combination chemotherapy for metastatic colorectal cancer are significantly associated with poor outcome. Oncology 79: 144-149. doi:10.1159/000320686. PubMed: 21150229.
27. Crocker M, Ashley S, Giddings I, Petrik V, Hardcastle A, et al. (2011) Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol 13: 99-108. doi:10.1093/neuonc/noq170. PubMed: 21163810.
28. Frederiksen C, Lomholt AF, Davis GJ, Dowell BL, Blankenstein MA, et al. (2009) Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. Anticancer Res 29: 75-81. PubMed: 19331135.
29. Guedez L, Stetler-Stevenson WG, (2010) The prognostic value of TIMP-1 in multiple myeloma. Leuk Res 34: 576-577. doi:10.1016/j.leukres.2009.10.005. PubMed: 19878997.
30. Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O, (2009) Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer. Gastric Cancer 12: 31-36. doi:10.1007/s10120-008-0494-3. PubMed: 19390929.
31. Yoshino Y, Kageshita T, Nakajima M, Funakubo M, Ihn H, (2008) Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and-2 in patients with malignant melanoma. J Dermatol 35: 206-214. doi:10.1111/j.1346-8138.2008.00446.x. PubMed: 18419677.
32. Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Rino Y, et al. (2007) Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology 72: 205-208. doi:10.1159/000112827. PubMed: 18160809.
33. Zagouri F, Sergentanis TN, Kalogera E, Provatopoulou X, Chrysikos D, et al. (2011) Serum MMPs and TIMPs: May be predictors of breast carcinogenesis? Clin Chim Acta 412: 537-540. doi:10.1016/j.cca.2010.11.037. PubMed: 21130755.
34. Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, et al. (2008) Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol 26: 2653-2658. doi:10.1200/JCO.2007.15.4336. PubMed: 18443351.
35. Brunckhorst MK, Wang H, Lu R, Yu Q, (2010) Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res 70: 7283-7293. doi:10.1158/0008-5472.CAN-09-4125. PubMed: 20823154.
36. Xu Y, Liu YJ, Yu Q, (2004) Angiopoietin-3 is tethered on the cell surface via heparan sulfate proteoglycans. J Biol Chem 279: 41179-41188. doi:10.1074/jbc.M400292200. PubMed: 15280392.
37. Murray LB, Lau YK, Yu Q, (2012) Merlin is a negative regulator of human melanoma growth. PLOS ONE 7: e43295. doi:10.1371/journal.pone.0043295. PubMed: 22912849.
38. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, et al. (2012) A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol 13: 1105-1113. doi:10.1016/S1470-2045(12)70263-2. PubMed: 23059047.
39. Rivette AS, Tokar EJ, Williams DE, Mackenzie CD, Ablin RJ, et al. (2005) Selection of cell lines with enhanced invasive phenotype from xenografts of the human prostate cancer cell line WPE1-NB26. J Exp Ther Oncol 5: 111-123. PubMed: 16471037.
40. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA, (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3: 349-363. doi:10.1038/nrm809. PubMed: 11988769.
41. Rønnov-Jessen L, Petersen OW, Bissell MJ, (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76: 69-125. PubMed: 8592733.
42. Servais C, Erez N, (2013) From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J Pathol 229: 198-207. doi:10.1002/path.4103. PubMed: 22996812.
43. Ostman A, Augsten M, (2009) Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr Opin Genet Dev 19: 67-73. doi:10.1016/j.gde.2009.01.003. PubMed: 19211240.
44. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, et al. (2008) TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133: 66-77. doi:10.1016/j.cell.2008.01.046. PubMed: 18394990.
45. Kawashiri S, Tanaka A, Noguchi N, Hase T, Nakaya H, et al. (2009) Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity. Head Neck 31: 1346-1353. doi:10.1002/hed.21097. PubMed: 19373786.
46. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348. doi:10.1016/j.cell.2005.02.034. PubMed: 15882617.
47. Wang J, Ying G, Jung Y, Lu J, Zhu J, et al. (2010) Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res 70: 471-480. doi:10.1158/1538-7445.AM10-471. PubMed: 20068185.
48. Jung YS, Liu XW, Chirco R, Warner RB, Fridman R, et al. (2012) TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLOS ONE 7: e38773. doi:10.1371/journal.pone.0038773. PubMed: 22701711.
49. Jung KK, Liu XW, Chirco R, Fridman R, Kim HR, (2006) Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 25: 3934-3942. doi:10.1038/sj.emboj.7601281. PubMed: 16917503.
50. Chirco R, Liu XW, Jung KK, Kim HR, (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25: 99-113. doi:10.1007/s10555-006-7893-x. PubMed: 16680576.
51. Luparello C, Avanzato G, Carella C, Pucci-Minafra I, (1999) Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 54: 235-244. doi:10.1023/A:1006121129382. PubMed: 10445422.
52. Liu H, Chen B, Lilly B, (2008) Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1. Angiogenesis 11: 223-234. doi:10.1007/s10456-008-9102-8. PubMed: 18273688.
53. Li G, Fridman R, Kim HR, (1999) Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59: 6267-6275. PubMed: 10626822.
54. Cai J, Tang H, Xu L, Wang X, Yang C, et al. (2012) Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis 33: 20-29. doi:10.1093/carcin/bgr230. PubMed: 22021907.
55. Shimoda M, Mellody KT, Orimo A, (2010) Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol 21: 19-25. doi:10.1016/j.semcdb.2009.10.002. PubMed: 19857592.
56. Zhang Y, Tang H, Cai J, Zhang T, Guo J, et al. (2011) Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett 303: 47-55. doi:10.1016/j.canlet.2011.01.011. PubMed: 21310528.